What if direct testing for fragile X were available to more IVF fragile X carrier candidates?

What if an embryo with a 56 CGG result was the only viable embryo? Current practice generally deems these embryos as not suitable, leaving a couple with less options.

What if we could give them more?

PEOPLE DESERVE BETTER ANSWERS.

Join us for an Exhibit Theater Presentation

Thursday, March 10, 2016 │ Exhibit Theater #1 │ 12:15 – 12:45 PM

“Single-cell fragile X molecular analysis and implications for pre-implantation genetic diagnosis”

Join Debra Lilienthal, MS, CGC from The Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine at Weill Cornell Medical College and Stela Filipovic-Sadic, R&D Scientist from Asuragen to hear about:

• Current common practice for fragile X PGD
• Benefits of direct fragile X PGD testing
• Latest research providing meaningful results from as little as a single cell

Visit Asuragen at Booth #521

Stop by the booth for a demonstration on the NEWAmplideX^® PCR/CE FMR1Reporter Software. Asuragen’s new fragile X reporting software.

There’s also a chance to win a $300 Shopping Spree! Be sure to stop by the booth for more details.